medigraphic.com

2003, Number 1

Next >>

Bioquimia 2003; 28 (1)

Immunology
Synthetic peptides of Trypanosoma cruzi for the immunodiagnostic of chagas' disease

Hernández-Marín M, Almenares-Guash P, Martínez-Ortiz C, Gómez-Cordero I, Melchor-Rodríguez A

Language: Spanish
References: 27
Page: 2-7
PDF size: 220.62 Kb.


ABSTRACT

Chagas´ disease is produced by one flagellate protozoan, the Trypanosoma cruzi (T. cruzi) using a technology for designing and obtaining synthetic peptides, which permits to achieve diagnostic techniques with high levels of sensitivity and specificity is a solution for serology diagnosis of Chagas´disease. This paper deals with use of two peptides (p17 and p18), obtained by chemical synthesis in solid phase, that corresponding to the immunodominant regions of Trypanosoma cruzi. The peptide p17 was synthesized as C-terminal (R-COOH) andamidopeptide (R-CONH2). The peptides were purified by Reverse Phase Cromatography HPLC and p17 (R-CONH2) and p18 peptideswere characterized by mass spectrometry MALDI-TOF. A biological activity of peptides was assayed in an immunoenzymatic assay. The peptide p17 (R-CONH2) had the best yield in chemical synthesis and immunoreactivity regarding to positive samples of Chagas, besides didn´t react with positives samples to Leishmania. Results showed that peptides that were achieved have good sensitivity and specificity and they´re very useful for diagnostic of Chagas disease.


REFERENCES

  1. Jorg ME, Tripanosomiasis cruzi humana o enfermedad de Chagas-Mazza. Rev Med Trop Sao Paulo 1978; 17 (1): 185-187.

  2. Mazzotti L, Díaz E. Resumen de los datos publicados sobre la enferme-dad de Chagas en México. Rev Soc Mex Hist Nat 1949; 10(1): 103-105.

  3. Aras R, Veiga M, Gómez I, Mota G, Rodríguez B, Rabelo R, et al.Prevalence of Chagas’ disease in Mulungu do Morro northeasternBrazil. Arq Bras Cardiol 2002; 78(5):441-443.

  4. Dias JC, Silveira AC, Schofield CJ. The impact of Chagas disease control inLatin America: a review. Mem Inst Oswaldo Cruz 2002; 97(5):603-612.

  5. Tay J, Biagi AMB. Localidades nuevas de triatóminos mexicanos y suinfección natural por Trypanosoma cruzi. Rev Fac Med 1984; 6(1):305-308.

  6. Dumonteil E, Gourbiere S, Barrera-Perez M, Rodríguez-Felix E, Ruiz-Pina H, Banos-López O, et al. Geographic distribution of Triatomadimidiata and transmission dynamics of Trypanosoma cruzi inthe Yucatan peninsula of Mexico. Am J Trop Med Hyg 2002;67(2):176-183.

  7. Schmuñiz G.A. Chagas disease and blood transfusion. Infect InmBlood Transfusion 1995; 127(1): 125-128.

  8. Winkler MA, Brashear RJ, Hall HJ, Schur JD, Pan AA. Detection ofantibodies to Trypanosoma cruzi among blood donors in the Southwestern and western United States. II. Evaluation of a supplementalenzyme immunoassay and radioimmunoprecipitation assay forconfirmation of seroreactivity. Transfusion 1995; 35(3): 219-225.

  9. Ferreira A, Belem W Z R, Moura M E G, Camargo M E. Aspectos dapadronização de testes sorológicos para doença de Chagas: um testeimunoenzimático para a triagem de doadores de sangue. Rev Inst MedTrop. S Paulo 1991; 33(2):123-128.

  10. Oelemann WMR, Teixeira MGM, Verissímo Da Costa G C. Evaluation ofthree commercial enzyme-linked immunoadsorbant assays for diagnosisof Chagas’ disease. J Clin Microbiol 1998; 36(9):2423-2427.

  11. Malchiodi EL, Chiaramante MG, Taranto NJ, Zwirner NW, Margni RA.Cross-reactivity studies and differential serodiagnosis of humaninfections causal by Trypanosoma cruzi and Leishmania spp; use ofimmunoblotting and ELISA with a purified antigen (Ag163B6). ClinExp Immunol 1994; 97(1): 417-420.

  12. Abramo C, Fontes CJ, Krettli AU. Cross-reactivity between antibodiesin the sera of individuals with leishmaniasis, toxoplasmosis, andChagas’ disease and antigens of the blood-stage forms of Plasmodiumfalciparum determined by indirect immunofluorescence. Am J Trop MedHyg 1995;53(2): 202-205.

  13. 13.Ferreira AW, Belem ZR, Lemus AA, Reed SG, Campos-Neto A. Enzyme-linked immunosorbent assay for serological diagnosis of Chagas’diseaseemploying a Trypanosoma cruzi recombinant antigen that consists offour different peptides. J Clin Microbiol 2001; 39(12): 4390-4395.

  14. Peralta JM, Teixeira MG, Shreffler WG, Pereira JB, Burns JM, Sleath PR,et al. Serodiagnosis of Chagas’ disease by enzyme-linkedimmunoadsorbant assay using two synthetic peptides as antigens. JClin Microbiol 1994; 32 (1): 971-994.

  15. Reed S G, inventor; Lasys Corporation, assignee. Peptide for diagnosisand immunizing against T. cruzi infections US Patent 5304371. 1992Feb 14.

  16. Reed S G, inventor; Lazys Corporation, assignee. Peptide for detectingantibodies to a 260 KD T. cruzi antigen US Patent 5413912. 1993 Dec 17.

  17. Burns JM, Shreffler WG, Rosman DE, Sleath PR, March CJ, Reed SG.Identification and synthesis of a major conserved antigenic epitopeof Trypanosoma cruzi. Proc Natl Acad Sci 1992; 89(4): 1239-1243.

  18. Merrifield RD. The synthesis of a tetrapeptide. J Am Chem Soc 1963;85: 2149-2151.

  19. Hudson D. Methodological implications of simultaneous solid-phasepeptide synthesis. I. Comparison of different coupling procedures. JOrg Chem 1988; 53(1): 617-620.

  20. Houghten RA, Bray MK, De Graw ST, Kirby CJ. Simplified procedurefor carrying out simultaneous multiple hydrogen fluoride cleavagesof protected peptide resins. Int J Pept Protein Res 1986; 27(1):673-675.

  21. Tam JP, Heath WF, Merrifield RB. SN2 deprotection of syntheticpeptides with a low concentration of HF in dimethyl sulfide: evidenceand application in peptide synthesis. J Am Chem Soc 1983; 105(1):6442-6444.

  22. Bucknall M, Fung KY, Duncan MW. Practical quantitative biomedicalapplications of MALDI-TOF mass spectrometry. J Am Soc Mass Spectrom2002; 13(9):1015-27.

  23. Umezawa E S, Bastos S F, Camargo M E, Yamauchi L M, Santos M R,González A, et al. Evaluation of recombinant antigens for serodiagnosisof Chagas’ disease in South and Central America. J Clin Microbiol1999; 37(5):1554-1560.

  24. Oelemann W M R, Teixeira M G M, Verissímo Da Costa G C. Evaluation ofthree commercial enzyme-linked immunoadsorbant assays for diagnosisof Chagas’ disease. J Clin Microbiol 1998; 36(9):2423-2427.

  25. Betonico GN, Miranda EO, Silva DA, Houghton R, Reed SG, Campos-NetoA, et al. Evaluation of a synthetic tripeptide as antigen for detectionof IgM and IgG antibodies to Trypanosoma cruzi in serum samples frompatients with Chagas disease or viral diseases. Trans R Soc Trop MedHyg 1999;93(6):603-606.

  26. Girones N, Rodríguez CI, Basso B, Bellon JM, Resino S, Munoz-FernándezMA, et al. Antibodies to an epitope from the Cha human autoantigenare markers of Chagas’ disease. Clin Diagn Lab Immunol 2001;8(6):1039-43.

  27. Vergara U, Veloso C, González A, Lorca M. Evaluation of an enzyme-linked immunosorbent assay for the diagnosis of Chagas’ diseaseusing synthetic peptides. Am J Trop Med Hyg 1992;46(1):39-43.




2020     |     www.medigraphic.com